Specialized Staff
Holy Name's medical and surgical oncologists specialize in specific cancers and work with other cancer experts, such as radiation oncologists, geneticists, and pathologists to formulate treatment plans unique to each patient. Click on a physician's name below for a detailed profile and to schedule an appointment.
Erika Brinkmann, MD, FACS
Chief of Breast Surgery
Board-certified in general surgery with a specialty in breast surgery, and a fellow of the American College of Surgeons, Dr. Brinkmann collaborates with all members of the Holy Name Medical Center breast health team in achieving the highest quality surgical results. Her goal is to provide breast care with compassion and in patient partnership to ensure each patient's quality of life.
Sharyn Lewin, MD, FACS, FACOG
Chief of Gynecologic Oncology, Ambassador, Medical Advisory Board, Sharsheret
Dr. Lewin is a board-certified gynecologic oncologist specializing in the diagnosis, treatment and management of ovarian, endometrial, uterine, cervical, vulvar and vaginal cancers. Her practice employs a comprehensive, multidisciplinary team approach for women at high risk for ovarian cancer and other gynecologic malignancies.
Yadyra Rivera, MD
Chief of Medical Oncology/Hematology
Yadyra Rivera, MD, is dual board certified in hematology and medical oncology, and fellowship–trained at respected academic medical centers in the New York metro area. She specializes in the use of chemotherapeutic drugs, immunotherapy, targeted and hormonal therapies, as well as treatment for pain and symptom management. She has been named a Top Doctor by Castle Connolly.
Maria Schiavone, MD
Gynecologic Oncologist
Dr. Maria B. Schiavone, a gynecologic oncologist, specializes in the diagnosis, medical/surgical treatment and lifelong medical care of women with benign and malignant conditions of the cervix, uterus, ovaries, vagina and vulva, as well as related malignancies of the upper abdomen, pelvic area and colorectal region. She has expertise in complex laparoscopic, robotic and open surgery; advanced chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC); targeted and hormonal therapies; and oral PARP inhibitors that enhance the effectiveness of chemotherapy.
